Ultrasound Historical Financial Summary

Significant Value Creation Opportunity Visibility to Growth Solid demand and backlog Continued R&D investment Commercial execution focus (GE HealthCare Expanding Adjusted EBIT Margin* Strategic pricing Higher-margin products Product line simplification % Revenue Growth 3% 2019A 2021A CAGR MSD % *-a) Medium-term Target % Adj. EBIT Margin* 15% - 18% High-teens to 20% Historic 2019A 2021A Medium-term Target Note: Illustrative graph, not to scale * Non-GAAP Financial Measure (a- on an organic basis Growth and Margin Expansion Driving Strong Shareholder Value © 2022, General Electric Company. Proprietary information. All rights reserved. 102

View entire presentation